Page 2194 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 2194
1943.e4 Part XII Hemostasis and Thrombosis
required for platelet adhesion and activation. J Exp Med 196:1057, 178. Berndt MC, Kabral A, Grimsley P, et al: An acquired Bernard-Soulier-
2002. like platelet defect associated with juvenile myelodysplastic syndrome.
154. Munday AD, Gaus K, Lopez JA: The platelet glycoprotein Ib-IX-V Br J Haematol 68:97, 1988.
complex anchors lipid rafts to the membrane skeleton: implications for 179. Cooper B, Schafer AI, Puchalsky D, et al: Platelet resistance to prosta-
activation-dependent cytoskeletal translocation of signaling molecules. glandin D2 in patients with myeloproliferative disorders. Blood 52:618,
J Thromb Haemost 8:163, 2010. 1978.
155. Liao JK: Isoprenoids as mediators of the biological effects of statins. 180. Horikawa Y, Matsumura I, Hashimoto K, et al: Markedly reduced
J Clin Invest 110:285, 2002. expression of platelet c-mpl receptor in essential thrombocythemia.
156. Heeschen C, Hamm CW, Laufs U, et al: Withdrawal of statins increases Blood 90:4031, 1997.
event rates in patients with acute coronary syndromes. Circulation 181. Moore A, Nachman RL: Platelet Fc receptor. Increased expression in
105:1446, 2002. myeloproliferative disease. J Clin Invest 67:1064, 1981.
157. Hackam DG, Woodward M, Newby LK, et al: Statins and intracerebral 182. Toyama K, Karasawa M, Yamane A, et al: JAK2-V617F mutation
hemorrhage: collaborative systematic review and meta-analysis. Circula- analysis of granulocytes and platelets from patients with chronic myelo-
tion 124:2233, 2011. proliferative disorders: advantage of studying platelets. Br J Haematol
158. Callahan KP, Malinin AI, Atar D, et al: Platelet activation as a universal 139:64, 2007.
trigger in the pathogenesis of acute coronary events after cocaine abuse. 183. Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in
Swiss Med Wkly 131:487, 2001. patients with essential thrombocythemia: relation to platelet, granulo-
159. Jennings LK, White MM, Sauer CM, et al: Cocaine-induced platelet cyte, and plasma hemostatic and inflammatory molecules. Exp Hematol
defects. Stroke 24:1352, 1993. 35:702, 2007.
160. Hobbs WE, Moore EE, Penkala RA, et al: Cocaine and specific cocaine 184. Panova-Noeva M, Marchetti M, Spronk HM, et al: Platelet-induced
metabolites induce von Willebrand factor release from endothelial cells thrombin generation by the calibrated automated thrombogram assay is
in a tissue-specific manner. Arterioscler Thromb Vasc Biol 33:1230, 2013. increased in patients with essential thrombocythemia and polycythemia
161. Dyerberg J, Bang HO: Haemostatic function and platelet polyunsatu- vera. Am J Hematol 86:337, 2011.
rated fatty acids in Eskimos. Lancet 2:433, 1979. 185. Castaman G, Lattuada A, Ruggeri M, et al: Platelet von Willebrand
162. Kim DN, Eastman A, Baker JE, et al: Fish oil, atherogenesis, and factor abnormalities in myeloproliferative syndromes. Am J Hematol
thrombogenesis. Ann N Y Acad Sci 748:474, 1995. 49:289, 1995.
163. Schoene NW: Vitamin E and omega-3 fatty acids: effectors of platelet 186. van Genderen PJ, Leenknegt H, Michiels JJ: The paradox of bleeding
responsiveness. Nutrition 17:793, 2001. and thrombosis in thrombocythemia: is von Willebrand factor the link?
164. Deykin D, Janson P, McMahon L: Ethanol potentiation of aspirin- Semin Thromb Hemost 23:385, 1997.
induced prolongation of the bleeding time. N Engl J Med 306:852, 187. van Genderen PJ, Leenknegt H, Michiels JJ, et al: Acquired von
1982. Willebrand disease in myeloproliferative disorders. Leuk Lymphoma
165. Rand ML, Jakubowski JA, Fisher MJ, et al: Ethanol enhances the 22(Suppl 1):79–82, 1996.
inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet 188. van Genderen PJ, Budde U, Michiels JJ, et al: The reduction of large
function. J Lab Clin Med 140:391, 2002. von Willebrand factor multimers in plasma in essential thrombocythae-
166. Nguyen A, Packham MA, Rand ML: Effects of ethanol on platelet mia is related to the platelet count. Br J Haematol 93:962, 1996.
responses associated with adhesion to collagen. Thromb Res 95:303, 189. Tiede A, Rand JH, Budde U, et al: How I treat the acquired von
1999. Willebrand syndrome. Blood 117:6777, 2011.
167. Hammerschmidt DE: Szechwan purpura. N Engl J Med 302:1191, 190. Shim K, Anderson PJ, Tuley EA, et al: Platelet-vWF complexes are
1980. preferred substrates of ADAMTS13 under fluid shear stress. Blood
168. Srivastava KC: Onion exerts antiaggregatory effects by altering arachi- 111:651, 2008.
donic acid metabolism in platelets. Prostaglandins Leukot Med 24:43, 191. Mohri H, Motomura S, Kanamori H, et al: Clinical significance of
1986. inhibitors in acquired von Willebrand syndrome. Blood 91:3623, 1998.
169. Apitz-Castro R, Badimon JJ, Badimon L: Effect of ajoene, the major 192. Bessler M, Mason PJ, Hillmen P, et al: Paroxysmal nocturnal haemo-
antiplatelet compound from garlic, on platelet thrombus formation. globinuria (PNH) is caused by somatic mutations in the PIG-A gene.
Thromb Res 68:145, 1992. EMBO J 13:110, 1994.
170. Srivastava KC: Extracts from two frequently consumed spices–cumin 193. Vu T, Griscelli-Bennaceur A, Gluckman E, et al: Aplastic anaemia and
(Cuminum cyminum) and turmeric (Curcuma longa)–inhibit platelet paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored
aggregation and alter eicosanoid biosynthesis in human blood platelets. proteins on human platelets. Br J Haematol 93:586, 1996.
Prostaglandins Leukot Essent Fatty Acids 37:57, 1989. 194. Fu R, Meng Y, Wang Y, et al: The dysfunction of platelets in paroxysmal
171. Kaur H, Corscadden K, Lott C, et al: Bromelain has paradoxical effects nocturnal hemoglobinuria. Thromb Res 148:50, 2016.
on blood coagulability: a study using thromboelastography. Blood 195. Steinberg D, Carvalho AC, Chesney CM, et al: Platelet hypersensitivity
Coagul Fibrinolysis 27:745, 2016. and intravascular coagulation in paroxysmal nocturnal hemoglobinuria.
172. Chaves DS, Frattani FS, Assafim M, et al: Phenolic chemical composi- Am J Med 59:845, 1975.
tion of Petroselinum crispum extract and its effect on haemostasis. Nat 196. Grunewald M, Grunewald A, Schmid A, et al: The platelet function
Prod Commun 6:961, 2011. defect of paroxysmal nocturnal haemoglobinuria. Platelets 15:145,
173. George JN, Shattil SJ: The clinical importance of acquired abnormali- 2004.
ties of platelet function. N Engl J Med 324:27, 1991. 197. Gralnick HR, Vail M, McKeown LP, et al: Activated platelets in
174. Barbui T, Barosi G, Grossi A, et al: Practice guidelines for the therapy paroxysmal nocturnal haemoglobinuria. Br J Haematol 91:697, 1995.
of essential thrombocythemia. A statement from the Italian Society 198. Lackner H, Hunt V, Zucker MB, et al: Abnormal fibrin ultrastructure,
of Hematology, the Italian Society of Experimental Hematology and polymerization, and clot retraction in multiple myeloma. Br J Haematol
the Italian Group for Bone Marrow Transplantation. Haematologica 18:625, 1970.
89:215, 2004. 199. Edelstein C, Scanu AM: Precautionary measures for collecting blood
175. Ashrani AA, Tefferi A, Pruthi RK, et al: Acquired factor V deficiency destined for lipoprotein isolation. Methods Enzymol 128:151, 1986.
in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. 200. Mehta J, Singhal S: Hyperviscosity syndrome in plasma cell dyscrasias.
Br J Haematol 171:875, 2015. Semin Thromb Hemost 29:467, 2003.
176. Carobbio A, Thiele J, Passamonti F, et al: Risk factors for arterial and 201. Kwaan HC: Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol
venous thrombosis in WHO-defined essential thrombocythemia: an Microcirc 55:75, 2013.
international study of 891 patients. Blood 117:5857, 2011. 202. Palmer RN, Rick ME, Rick PD, et al: Circulating heparan sulfate
177. Ginsburg AD: Platelet function in patients with high platelet counts. anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med
Ann Intern Med 82:506, 1975. 310:1696, 1984.

